Thomas O. Hecht
Chairman chez AFFIMED N.V.
Fortune : 13 M $ au 31/03/2024
Provenance du réseau au premier degré de Thomas O. Hecht
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
34
| Public Company | Biotechnology | 34 |
| Public Company | Biotechnology | 21 | |
Cytos Biotechnology AG
 Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland.
17
| Extinct | Miscellaneous Commercial Services | 17 |
Kuur Therapeutics Ltd.
 Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom.
12
| Subsidiary | Pharmaceuticals: Major | 12 |
Aelix Therapeutics SL
 Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain.
9
| Holding Company | Biotechnology | 9 |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.
9
| Subsidiary | Miscellaneous Commercial Services | 9 |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.
6
| Subsidiary | Miscellaneous Commercial Services | 6 |
Orion Biotechnology Canada Ltd.
 Orion Biotechnology Canada Ltd. BiotechnologyHealth Technology Orion Biotechnology Canada Ltd. operates as pharmaceutical company. The company was founded by Rudolf Bom in 2011 and is headquartered in Ottawa, Canada.
6
| Holding Company | Biotechnology | 6 |
Cell Medica Switzerland AG
 Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland.
4
| Subsidiary | Pharmaceuticals: Major | 4 |
SuppreMol GmbH
 SuppreMol GmbH Pharmaceuticals: MajorHealth Technology SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany.
3
| Subsidiary | Pharmaceuticals: Major | 3 |
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland.
2
| Subsidiary | Miscellaneous Commercial Services | 2 |
Humabs BioMed SA
 Humabs BioMed SA Miscellaneous Commercial ServicesCommercial Services Humabs BioMed SA is an antibody therapeutics biotechnology company. It develops human monoclonal antibody platforms for treatment of infectious and inflammatory diseases. The company was founded by Prof. Antonio Lanzavecchia on October 24, 2011 and is headquartered in Bellinzona, Switzerland.
1
| Subsidiary | Miscellaneous Commercial Services | 1 |
Amgen (Europe) GmbH
1
| Subsidiary | 1 | |
Affimed AG
1
| Private Company | 1 | |
Haemosan, Inc.
 Haemosan, Inc. Regional BanksFinance Haemosan, Inc. operates as a bank holding company. The company was founded on August 20, 1979 and is headquartered in Mount-Royal, Canada.
1
| Private Company | Regional Banks | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Thomas O. Hecht via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| DEUTSCHE BANK AG | Investment Banks/Brokers | Corporate Officer/Principal Corporate Officer/Principal | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ONCOLYTICS BIOTECH INC. | Biotechnology | Director/Board Member Director/Board Member | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| FIVE PRIME THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
PARI Pharma GmbH
 PARI Pharma GmbH Pharmaceuticals: MajorHealth Technology PARI Pharma GmbH Manufactures inhalant drugs. It offers aerosol inhalats and nebulizers which are primarily used against respiratory conditions. The company was founded in 1997 and is headquartered in Starnberg, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Abingworth Management Ltd.
 Abingworth Management Ltd. Investment ManagersFinance Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom. | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
| The Trustees of Columbia University in The City of New York | College/University | Graduate Degree Undergraduate Degree Masters Business Admin | |
| University of Pennsylvania | College/University | Undergraduate Degree Graduate Degree | |
| EVOTEC SE | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
| MORPHOSYS AG | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Public Communications Contact | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) MiscellaneousMiscellaneous Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Miscellaneous | Corporate Officer/Principal Chief Investment Officer | |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Imperial College London | College/University | Doctorate Degree Graduate Degree | |
Van Herk Investments BV
 Van Herk Investments BV Investment ManagersFinance Van Herk Investments BV (VHI) is the private equity investment arm of the Van Herk Groep BV, based in Rotterdam. The parent firm was established in the 1950s as a family business with a focus on real estate investments. VHI invests in listed and unlisted firms across diverse sectors primarily in The Netherlands. | Investment Managers | Director of Finance/CFO Private Equity Investor | |
| The University of Chicago | College/University | Undergraduate Degree Masters Business Admin | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
Agendia NV
 Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Affimed NV Niederlassung Deutschland
 Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer | |
| University of Lund | College/University | Undergraduate Degree Masters Business Admin Undergraduate Degree | |
| University of Barcelona | College/University | Undergraduate Degree Doctorate Degree | |
| Erasmus University Rotterdam | College/University | Undergraduate Degree Graduate Degree Doctorate Degree | |
| University of Hannover | College/University | Undergraduate Degree Doctorate Degree | |
| University of Basel | College/University | Doctorate Degree Director/Board Member Undergraduate Degree | |
| Johann Wolfgang Goethe-Universität Frankfurt am Main | College/University | Doctorate Degree Doctorate Degree | |
| University of Zurich | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree | |
| Freie Universität Berlin | College/University | Doctorate Degree Doctorate Degree | |
| University of Bielefeld | College/University | Doctorate Degree Doctorate Degree | |
| Philipps University of Marburg | College/University | Graduate Degree Doctorate Degree | |
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree Graduate Degree | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
venBio Partners LLC
 venBio Partners LLC Investment ManagersFinance venBio Partners LLC (venBio) is a private equity subsidiary of Venbio Partners LP founded in 2009 by Adelman robert and Goodman corey. The firm is headquartered in San Francisco, California. | Investment Managers | Founder Founder | |
Agendia, Inc.
 Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| SENSORION | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| MENDUS AB | Biotechnology | Director/Board Member Director/Board Member | |
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Drugstore Chains | Director/Board Member Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Undergraduate Degree | |
SkylineDx BV
 SkylineDx BV Medical/Nursing ServicesHealth Services SkylineDx BV develops molecular diagnostic tests for blood cancers. The firm focuses on the development and commercialization of gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. Its products include MMprofiler and AMLprofiler. The company was founded by Dharminder S. Chahal and Bob Löwenberg in 2005 and is headquartered in Rotterdam, the Netherlands. | Medical/Nursing Services | Director of Finance/CFO Director/Board Member Chief Executive Officer | |
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| KUROS BIOSCIENCES AG | Biotechnology | Director/Board Member Director/Board Member Director of Finance/CFO Chairman | |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Biotechnology | Chief Executive Officer Director/Board Member | |
Exevir Bio BV
 Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Vectura GmbH
 Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Medical Specialties | Director/Board Member Director of Finance/CFO | |
| New York University School of Medicine | College/University | Doctorate Degree Corporate Officer/Principal |
Statistiques
Internationale
| Etats-Unis | 15 |
| Allemagne | 13 |
| Suisse | 7 |
| Royaume-Uni | 5 |
| Pays-Bas | 5 |
Sectorielle
| Health Technology | 19 |
| Consumer Services | 19 |
| Finance | 9 |
| Health Services | 4 |
| Miscellaneous | 2 |
Opérationnelle
| Director/Board Member | 459 |
| Corporate Officer/Principal | 171 |
| Independent Dir/Board Member | 92 |
| Chief Executive Officer | 70 |
| Director of Finance/CFO | 69 |
Relations les plus connectées
| Insiders | |
|---|---|
| Annalisa Jenkins | 51 |
| Jörg Neermann | 34 |
| Kurt von Emster | 34 |
| Paul Brooke | 32 |
| Nanna Liebach Lüneborg | 29 |
| Jason G. Burke | 27 |
| Ferdinand Verdonck | 25 |
| Dharminder Singh Chahal | 25 |
| Thomas Dyrberg | 24 |
| Berndt A. E. Modig | 23 |
| Bernd Seizinger | 23 |
| Vincent Ossipow | 22 |
| Leonard Kruimer | 22 |
| Julia Gregory | 22 |
| Mathieu Simon | 22 |
- Bourse
- Insiders
- Thomas O. Hecht
- Connexions Sociétés
